Please login to the form below

Not currently logged in
Email:
Password:

Lilly names Plowman as oncology research chief

Eli Lilly has selected Greg Plowman, formerly senior director at Roche Group's Genentech, to lead its oncology research efforts

Eli Lilly and Company has appointed Greg Plowman as the vice president, oncology research and senior vice president of ImClone Systems research.

Plowman will oversee the oncology research efforts of Lilly and its subsidiary, ImClone. Plowman will be based at ImClone's Alexandria Center for Life Science in New York City, US.

Plowman served as a senior director in research for six years at Genentech, a member of the Roche Group. He has 25 years of experience in cancer research including leadership roles at Oncogene, Sugen, Exelixis and Genentech, which became part of Bristol-Myers Squibb, Pharmacia and Roche.

Lilly acquired ImClone in 2008, broadening its portfolio and strengthening its oncology pipeline and biotech capabilities. The company has one of the largest clinical-stage pipelines of potential cancer medicines in the industry with more than 30 molecules.

 

10th March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...

Infographics